Partner Headlines - BMY

  1. Eliquis revives Bristol-Myers

    IBD
  2. Bristol-Myers Beats Q3 Views As Eliquis Revives

    IBD
  3. Stocks Flat In Mixed Volume; Amazon.com Weighs On Techs

    IBD
  4. UPDATE: Bristol-Myers Squibb Q3 Earnings Top Estimates

    Benzinga
  5. Stock Futures Aim For Flat Open; Amazon.com Crumples On Q3 Miss

    IBD
  6. #PreMarket Primer: Friday, October 24: Ebola Fears Weigh On Markets

    Benzinga
  7. Earnings Scheduled For October 24, 2014

    Benzinga
  8. Must Watch Stocks for Today

    Benzinga
  9. Stocks Rebound; Amazon.com Slides After Hours

    IBD
  10. Drug ETFs Attractive Buys On Pullback

    Benzinga
  11. Weekly CFO Sells Highlight: Williams Companies Inc, Google Inc, ...

    GuruFocus
  12. Benzinga Weekly Preview: Earnings Season Is In Full Swing

    Benzinga
  13. Apple Leads the Charge as Earnings Season Heats Up

    FoxBusiness
  14. The Six Types of Winning Stocks

    GuruFocus
  15. Markets Debut Week On Negative Note; S&P 500 Falls Through Key ...

    Benzinga
  16. Merck to release hep C data

    IBD
  17. Merck, Bristol, Arrowhead Prep Hepatitis Studies

    IBD
  18. Salix, Actavis Among Big Cap Pharmas In Merger Mambo

    IBD
  19. Bristol-Myers pulls FDA filing

    IBD
  20. Bristol-Myers Pulls FDA Filing For 2-Drug Hep C Combo

    IBD
  21. Bristol-Myers Squibb Statement About Asunaprevir In The US, WIthdraws ...

    Benzinga
  22. 2 Mutual Funds Holding Hospital Stocks

    Benzinga
  23. NeurOp Receives Milestone Payment As Bristol-Myers Squibb Nominates ...

    Benzinga
  24. Morgan Stanley Believes Bristol-Myers Squibb Co. Could Move Significantly ...

    Benzinga
  25. Gilead's New HIV Drug Key To Long-Term Strategy

    IBD
  26. Gilead OKs Generic Sovaldi To Expand Global Access

    IBD
  27. Bristol-Myers Squibb Co In Patent Suit Vs. Merck & Co., Inc. ...

    Benzinga
  28. Merck PD-1 Inhibitor Approved For Skin Cancer

    IBD
  29. Drug M&A Boom Driven By Long-Term Trends: PwC

    IBD
  30. Booming Biotech Market Benefits REIT BioMed Realty

    IBD
  31. Bristol-Myers: Absolute Valuation Model versus Relative Valuation ...

    GuruFocus
  32. Bristol-Myers Drug Gets OK

    IBD
  33. Markets Little Changed In Low Volume And Slow News Ahead Of Long ...

    Benzinga
  34. Deutsche Bank Starts Pfizer, Lilly at Buy, Merck, Bristol-Myers ...

    Benzinga
  35. Bristol-Myers Hepatitis C Therapy Approved in EU

    IBD
  36. US Stock Futures Edge Higher Ahead Of Tiffany Earnings

    Benzinga
  37. Merck, Pfizer Combining Drugs In Lung Cancer Study

    IBD
  38. Intercept Pharma Soars On Liver-Disease Drug Data

    IBD
  39. Markets Marginally Higher On Light Volume And Encouraging Geopolitical ...

    Benzinga
  40. Drugmaker AstraZeneca Returns To Growth

    IBD
  41. The Stocks Already in Correction Mode

    FoxBusiness
  42. Will ImmunoGen's Q4 Earnings Disappoint Again?

    GuruFocus
  43. Bristol-Myers surprises Street

    IBD
  44. Thursday Morning Earnings Reports

    Benzinga
  45. Stock Futures Steer Higher; Facebook, Skechers Nail Q2 Wins

    IBD
  46. Earnings Scheduled For July 24, 2014

    Benzinga
  47. Facebook, Gilead Headline IBD 50's Top 5 Earnings

    IBD
  48. Benzinga Weekly Preview: Earnings Season Continues With Geopolitical ...

    Benzinga
  49. UnitedHealth Group Up on Weak Day for the Dow

    GuruFocus
  50. Dow Sets New Intraday High; Citigroup Impresses With Earnings

    Benzinga
  51. Senators Ask Gilead To Explain Sovaldi Pricing

    IBD
  52. Bristol seeks cancer drug nod

    IBD
  53. Bristol-Myers Seeking Nivolumab Approval In Melanoma

    IBD
  54. Japan approves BMY regimen

    IBD
  55. Jazz, Novo Among Medicals Showing Healthy Action

    IBD
  56. Bristol-Myers' All-Oral HCV Therapy Approved In Japan

    IBD
  57. Merck, Gilead Lead Race To Eradicate Hepatitis C

    IBD
  58. Markets Little Changed Ahead Of 4th Of July Break

    Benzinga
  59. Barclays Downgrades Pharmaceutical Sector

    Benzinga
  60. UPDATE: Barclays Downgrades Bristol-Myers, Cuts Price Target ...

    Benzinga
  61. Benzinga's Top Downgrades

    Benzinga
  62. Ex-Dividends For July 1, 2014

    Benzinga
  63. Pfizer and others get EU nods

    IBD
  64. Bristol-Myers, Pfizer, Regeneron Drugs Get EU Nods

    IBD
  65. Pfizer, Bristol-Myers Squibb Announce Positive Opinion For Treatments

    Benzinga
  66. US Stock Futures Drop Ahead Of Consumer Sentiment Report

    Benzinga
  67. Bristol-Myers Squibb Receives Positive CHMP Opinion for Daklinza ...

    Benzinga
  68. Pharma Sector Stocks To Consider For Sustained Returns

    GuruFocus
  69. Bristol-Myers Stock Up On Nivolumab Trial Success

    IBD
  70. BRISTOL-MYERS SQUIBB

    IBD
  71. UPDATE: Bristol Myers Announces Phase 3 First-Line Study of Nivolumab ...

    Benzinga
  72. Benzinga's M&A Chatter for Monday June 16, 2014

    Benzinga
  73. Merck Takes The 'Nuc' Option In Hepatitis C Race

    IBD
  74. ASCO Meeting Day 4: Risks And Rewards Of Immunotherapy

    Benzinga
  75. ASCO Meeting Day 3: Do More Treatments Equal A Longer Life?

    Benzinga
  76. Bristol-Myers Offers Two-, Three-Year Survival Data for Nivolumab

    Benzinga
  77. AstraZeneca Woos Shareholders With Promise Of Growth

    IBD
  78. Vanguard Health Care Fund's Top Quarterly Holdings

    GuruFocus
  79. Bristol, Merck Q1 sales soft

    IBD
  80. Bristol, Merck, Sanofi Report Soft Q1 Sales

    IBD
  81. ETF Outlook For Tuesday, April 29, 2014 (IHE, TAN, XRT, SOCL, ...

    Benzinga
  82. UPDATE: Bristol-Myers Posts Higher Q1 Profit

    Benzinga
  83. US Stock Futures Up Ahead Of Earnings, Consumer Confidence Data

    Benzinga
  84. Bristol-Myers Squibb Acquires iPierian for $175M, Potential Milestone ...

    Benzinga
  85. Earnings Scheduled For April 29, 2014

    Benzinga
  86. Stocks To Watch For April 29, 2014

    Benzinga
  87. Pfizer Confirms Pursuit Of AstraZeneca; Stocks Jump

    IBD
  88. Earnings Expectations For The Week Of April 28: Big Oil, Big ...

    Benzinga
  89. Benzinga Weekly Preview: Earnings Season Continues As Biotech ...

    Benzinga
  90. Week Ahead: April Jobs Report, FOMC Meeting and Earnings

    FoxBusiness
  91. Pfizer, AstraZeneca Rise On Report Of Merger Talks

    IBD
  92. UPDATE: Bristol-Myers Squibb Submits NDA to US FDA for Fixed-Dose ...

    Benzinga
  93. Investors: Brace for a Turbulent Second Quarter

    FoxBusiness
  94. Amgen Stock Gets Bump Up On Cholesterol Drug Data

    IBD
  95. Gilead Sovaldi Scrips Falter As Biotechs Keep Falling

    IBD
  96. Which Pharmas Can Keep Up Dividend-Buybacks?

    YCharts
  97. Novo Nordisk Upgraded to 'Buy'

    FoxBusiness
  98. Abbvie Inc. (ABBV) Dividend Stock Analysis

    GuruFocus
  99. Gilead's HCV Challengers Near The Starting Gate

    IBD
  100. Gilead's HCV Challengers Near The Starting Gate

    IBD
Trading Center